Folgen
Anne Searls De Groot
Anne Searls De Groot
Sonstige NamenAnne S. DeGroot, Anne DeGroot, Annie De Groot
EpiVax, Inc and (formerly) Center for Vaccines and Immunology, UGA
Bestätigte E-Mail-Adresse bei epivax.com - Startseite
Titel
Zitiert von
Zitiert von
Jahr
Immunogenicity of protein therapeutics
AS De Groot, DW Scott
Trends in immunology 28 (11), 482-490, 2007
6242007
Activation of natural regulatory T cells by IgG Fc–derived peptide “Tregitopes”
AS De Groot, L Moise, JA McMurry, E Wambre, L Van Overtvelt, ...
Blood, The Journal of the American Society of Hematology 112 (8), 3303-3311, 2008
4502008
T-cell dependent immunogenicity of protein therapeutics: preclinical assessment and mitigation
V Jawa, LP Cousens, M Awwad, E Wakshull, H Kropshofer, AS De Groot
Clinical immunology 149 (3), 534-555, 2013
2672013
Immuno‐informatics: Mining genomes for vaccine components
AS De Groot, H Sbai, CS Aubin, J McMurry, W Martin
Immunology and cell biology 80 (3), 255-269, 2002
2552002
From genome to vaccine: in silico predictions, ex vivo verification
AS De Groot, A Bosma, N Chinai, J Frost, BM Jesdale, MA Gonzalez, ...
Vaccine 19 (31), 4385-4395, 2001
2502001
Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics
AS De Groot, W Martin
Clinical immunology 131 (2), 189-201, 2009
2382009
Two novel T cell epitope prediction algorithms based on MHC-binding motifs; comparison of predicted and published epitopes from Mycobacterium tuberculosis and HIV protein sequences
GE Meister, CGP Roberts, JA Berzofsky, AS De Groot
Vaccine 13 (6), 581-591, 1995
2151995
Immunomics: discovering new targets for vaccines and therapeutics
AS De Groot
Drug discovery today 11 (5-6), 203-209, 2006
1992006
Emerging vaccine informatics
Y He, R Rappuoli, AS De Groot, RT Chen
BioMed Research International 2010, 2010
1832010
Clinical validation of the “in silico” prediction of immunogenicity of a human recombinant therapeutic protein
E Koren, AS De Groot, V Jawa, KD Beck, T Boone, D Rivera, L Li, ...
Clinical Immunology 124 (1), 26-32, 2007
1682007
Prediction of well-conserved HIV-1 ligands using a matrix-based algorithm, EpiMatrix
JRA Schafer, BM Jesdale, JA George, NM Kouttab, AS De Groot
Vaccine 16 (19), 1880-1884, 1998
1521998
Tregitope update: mechanism of action parallels IVIg
LP Cousens, R Tassone, BD Mazer, V Ramachandiran, DW Scott, ...
Autoimmunity Reviews 12 (3), 436-443, 2013
1422013
From genome to vaccine—new immunoinformatics tools for vaccine design
AS De Groot, JA Berzofsky
Methods 4 (34), 425-428, 2004
1402004
An interactive Web site providing major histocompatibility ligand predictions: application to HIV research
AS De Groot, BM JESDALE, E SZU, JR SCHAFER, RM CHICZ, ...
AIDS research and human retroviruses 13 (7), 529-531, 1997
1401997
Prediction of immunogenicity for therapeutic proteins: state of the art
AS De Groot, L Moise
Current Opinion in Drug Discovery and Development 10 (3), 332, 2007
1352007
Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates
AS De Groot, J McMurry, L Moise
Current opinion in pharmacology 8 (5), 620-626, 2008
1322008
In vitro and in vivo studies of IgG-derived Treg epitopes (Tregitopes): a promising new tool for tolerance induction and treatment of autoimmunity
LP Cousens, N Najafian, F Mingozzi, W Elyaman, B Mazer, L Moise, ...
Journal of clinical immunology 33, 43-49, 2013
1312013
Immunoinformatic comparison of T-cell epitopes contained in novel swine-origin influenza A (H1N1) virus with epitopes in 2008–2009 conventional influenza vaccine
AS De Groot, M Ardito, EM McClaine, L Moise, WD Martin
Vaccine 27 (42), 5740-5747, 2009
1282009
Mapping cross-clade HIV-1 vaccine epitopes using a bioinformatics approach
AS De Groot, B Jesdale, W Martin, C Saint Aubin, H Sbai, A Bosma, ...
Vaccine 21 (27-30), 4486-4504, 2003
1182003
T cell epitope: friend or foe? Immunogenicity of biologics in context
CA Weber, PJ Mehta, M Ardito, L Moise, B Martin, AS De Groot
Advanced drug delivery reviews 61 (11), 965-976, 2009
1152009
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20